Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
336
days
Emerging biological drugs for the treatment of patients with metastatic HER2+ gastroesophageal adenocarcinomas
AuthorsJane E. Rogers; Ashley Horak; Alicia Kroll; Jaffer A. Ajani
Affiliations1. U.T. M.D. Anderson Cancer Center; 2. U.T.M.D. Anderson Cancer Center
195
days
At the forefront of gene-based therapies in Dravet syndrome
AuthorsAntonella Riva; Sara Di Gioacchino; Greta Volpedo; Beatrice Risso; Antonella De Lillo; Federico Zara; Antonio Falace; Pasquale Striano
Affiliations1. University of Genoa; 2. IRCCS Istituto “Giannina Gaslini”, Full Member of ERN EpiCARE
29
days
σ 1 receptor agonists: the new trend or an emerging therapeutic option?
AuthorsTangui Maurice
Affiliations1. University of Montpellier, EPHE, INSERM
236
days
Evaluating emerging amyloid-β centric drugs for the treatment of Alzheimer's disease
AuthorsMadia Lozupone; Vittorio Dibello; Rodolfo Sardone; Roberta Zupo; Fabio Castellana; Ilaria Bortone; Luisa Lampignano; Michela Di Matteo; Giuseppe Moramarco; Flora Dellegrazie; Antonio Daniele; Vincenzo Solfrizzi; Francesco Panza
Affiliations1. Local Health Authority of Bari; 2. University of Bari Aldo Moro; 3. University of Bari “Aldo Moro”; 4. University of Amsterdam and Vrije Universiteit Amsterdam; 5. Local Healthcare Authority of Taranto; 6. Local Healthcare Authority of Bari; 7. Catholic University of Sacred Heart; 8. IRCCS Fondazione Policlinico Universitario A. Gemelli
87
days
Obefazimod (ABX464) for moderate-to-severe Crohn’s disease: clinical development of a novel oral therapeutic approach
AuthorsSailish Honap; Axel Dignass; Vipul Jairath; Fernando Magro; Silvio Danese; Laurent Peyrin-Biroulet
Affiliations1. St George’s University Hospitals NHS Foundation Trust; 2. King’s College London; 3. Goethe University; 4. Western University; 5. Faculdade de Medicina da Universidade do Porto; 6. IRCCS Ospedale San Raffaele; 7. McGill University Health Centre
77
days
Emerging treatment options for chronic obstructive pulmonary disease: a look into 2026 and beyond
AuthorsCarolyn J. Wang; Clarus Leung; Don D. Sin
Affiliations1. St. Paul’s Hospital; 2. The University of Western Australia; 3. University of British Columbia
66
days
Acute management of adult MOG antibody–associated disease: therapeutic choices and clinical outcomes
AuthorsEdgar Carnero Contentti; Eoin P. Flanagan; Ethel Ciampi
Affiliations1. Hospital Alemán; 2. INECO Neurociencias Oroño; 3. Mayo Clinic College of Medicine; 4. Pontificia Universidad Católica de Chile; 5. Red de Salud UC CHRISTUS; 6. Hospital Dr Sotero del Rio
48
days
Beyond triptans in menstrual migraine: the emerging role of CGRP-targeted therapies
AuthorsLanfranco Pellesi; Damiana Scuteri; Andrea Burgalassi; Alberto Chiarugi; Paolo Martelletti
Affiliations1. University of Southern Denmark; 2. University “Magna Graecia” of Catanzaro; 3. Careggi University Hospital; 4. Unitelma Sapienza University of Rome
95
days
Emerging small molecules for ulcerative colitis: clinical advancements and trial insights
AuthorsCristina Lanzotti; Fabrizio Fanizzi; Ferdinando D’Amico; Alessandra Zilli; Federica Furfaro; Mariangela Allocca; Virginia Solitano; Clelia Cicerone; Sara Massironi; Tommaso Lorenzo Parigi; Laurent Peyrin-Biroulet; Silvio Danese
Affiliations1. IRCCS San Raffaele Hospital; 2. Vita-Salute San Raffaele University; 3. Istituti Ospedalieri Bergamaschi; 4. INFINY Institute, CHRU Nancy
135
days
Emerging claudin-18.2 antagonists in the treatment of biliary tract cancer
AuthorsDaniel Neureiter; Dino Bekric; Christian Mayr; Tobias Kiesslich; Matthias Ocker
Affiliations1. Paracelsus Medical University/University Hospital Salzburg (SALK); 2. Cancer Cluster Salzburg; 3. Paracelsus Medical University; 4. University Clinics Salzburg, Paracelsus Medical University; 5. Campus Charité Mitte, Charité University Medicine Berlin; 6. EO Translational Insights Consulting GmbH; 7. Tacalyx GmbH
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days